Genesis Therapeutics

We’re a hybrid AI + biotech company, developing novel neural networks to predict molecular properties and using them to accelerate the development of new medicines. Small team of excellent software engineers: graduates from Stanford, UC Berkeley, MIT. Previously worked at Facebook, Google, Memsql, Jane Street. Core deep learning tech was invented by co-founder + CEO Evan Feinberg during his PhD at Stanford’s Pande lab. Recently raised a $4.1m seed round led by Andreessen Horowitz. Our platform was validated in collaboration with a top-five pharma company. In addition to strong software + AI talent, our small team has top drug discovery chemists who have collectively discovered several FDA-approved drugs before.